Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire takes Proactive's Stephen Gunnion through the leader in longevity research's recent progress and plans.
Leire highlighted three main events. Firstly, the successful securing of funding has enabled the company to advance its programs without delays. Specifically, the focus on lead candidate, GF-1002, has seen significant progress thanks to the guidance from the FDA and the European Agency.
Leire emphasised the importance of maintaining a global reach, aligning efforts in both Europe and the US to maximize market potential.
Leire shared insights on Genflow's innovative approach to delivering sirtuin 6 (SIRT6) variants, particularly in veterinary applications, which has led to promising developments in clinical trials for dogs. This research not only aims to combat age-related diseases in animals but also provides crucial data that could expedite human trials.
Moreover, Genflow's collaboration with Exothera S.A. on a feasibility study for large-scale production of sirtuin 6 variants is a key step towards cost-effective therapies.
As Genflow moves into the second half of 2024, the primary focus will be on preparing for clinical trials on MASH (metabolic-associated steatohepatitis). and advancing the dog study, which could lead to rapid proof of concept and potential collaborations with major veterinary pharmaceutical companies.
"Our commitment to advancing these programs while ensuring cost-effectiveness and broad market reach is unwavering," said Dr Leire.